Franklin Resources
ALLO icon

Franklin Resources’s Allogene Therapeutics ALLO Stock Holding History

Franklin Resources’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,853
Closed -$78.8K – 2640
2023
Q3 		$78.8K Buy
24,853
+1,277
+5% +$5.6K ﹤0.01% 2483
2023
Q2 		$117K Buy
+23,576
New +$128K ﹤0.01% 2513
2020
Q1 		– Sell
-610,697
Closed -$15.9M – 1478
2019
Q4 		$15.9M Sell
610,697
-178,082
-23% -$4.9M 0.01% 810
2019
Q3 		$21.5M Hold
788,779
– – 0.01% 728
2019
Q2 		$21.2M Sell
788,779
-200
-0% -$5.57K 0.01% 732
2019
Q1 		$22.6M Buy
788,979
+289,797
+58% +$8.41M 0.01% 714
2018
Q4 		$13.4M Buy
+499,182
New +$13.3M 0.01% 814

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Franklin Resources's ALLO Position: Q4 2023 in Review

Franklin Resources sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 24,853 shares — an estimated $78.8K sold.

Franklin Resources first reported a position in ALLO in Q4 2018 and held it in 7 quarters. The position peaked at $22.6M in Q1 2019. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

  • Franklin Resources reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Franklin Resources sold 24,853 Allogene Therapeutics shares in Q4 2023, an estimated $78.8K.
  • Franklin Resources first reported a position in Allogene Therapeutics in Q4 2018 and held it in 7 quarters.
  • Franklin Resources's Allogene Therapeutics position peaked at $22.6M in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Franklin Resources's 13F filing for Q4 2023, filed 9 Feb 2024.